Results 161 to 170 of about 17,658 (223)

Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progress. [PDF]

Pleura Peritoneum
Popat V, Frankel PH, Ruel NH, Yost SE, Chang S, Wang E, Villella J, Whyte J, Whelan RL, Eng M, Tinsley R, Synold T, Han E, Song M, Cohen J, Raoof M, Dellinger TH.   +16 more
europepmc   +1 more source

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study. [PDF]

Ther Adv Med Oncol
Escriva-Aranda C, Giner-Moreno E, Soria Hernández E, Esteve Gallego J, Gómez Roch E, Capdevila P, Carrasco Picazo C, Ortiz Gracia A, Vidal Jiménez D, Aparicio J, Díaz Beveridge R.   +10 more
europepmc   +1 more source

Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study. [PDF]

Signal Transduct Target Ther
Zhang X, Wei J, Chen N, Liu K, Liang R, Ma L, Song Z, Gu X, Chen X, Yang S.   +9 more
europepmc   +1 more source

Re-evaluating treatment strategies: a closer look at the FOLFOX-nab-Paclitaxel approach in the immunotherapy era for metastatic gastric cancer. [PDF]

Oncologist
Cetınkaya AM, Ilhan Y.
europepmc   +1 more source

Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year Retrospective Audit. [PDF]

Cureus
Ramidi GR, Yadav R, Patnaik A, Sunny G.
europepmc   +1 more source

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. [PDF]

ESMO Open
Kahl T, Eisenring SD, Liposits G.
europepmc   +1 more source

Determinants of eligibility for second-line chemotherapy following gemcitabine plus nab-paclitaxel therapy in patients with unresectable pancreatic cancer: a retrospective study. [PDF]

BMC Gastroenterol
Ueda T, Miyagawa K, Shibata M, Mori Y, Oe S, Kajitani K, Uchihara D, Shinohara N, Ogino N, Kumei S, Honma Y, Watanabe T, Harada M.   +12 more
europepmc   +1 more source

Nab-paclitaxel plus S-1 induction chemotherapy for patients with locally advanced pancreatic cancer: a multicenter, open-label phase 2 study. [PDF]

Signal Transduct Target Ther
Cao Z, Qiu J, Luo W, Li J, Chen H, Liu Y, Li S, Li F, Yang Y, Cheng Y, Zhang T, Xue H, Bai C, Zhao Y.   +13 more
europepmc   +1 more source

FOLFIRINOX vs. Gemcitabine/Nab-Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C-CAT Database Study. [PDF]

Cancer Sci
Mizuno K, Ishikawa T, Ito T, Takano Y, Maeda O, Kawashima H, Ando Y.   +6 more
europepmc   +1 more source

Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer. [PDF]

Cancer Med
Wang Y, Zhang WJ, Lu YX, Liu SL, Zhang ZY, Zhang SM, Wang TW, Zhong Y, Zhang DS.   +8 more
europepmc   +1 more source